Readily Diagnostics
Readily Diagnostics develops molecular tests that help clinicians identify infectious diseases near the patient without relying on a central laboratory.
~$970KGates Foundation grant
ParticipantGF
Gates Foundation
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Europe · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $45.4M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionLeyden Laboratories
Develops antibody-based nasal sprays intended to prevent influenza and other respiratory-virus infections.
€40MSeries B
Role not disclosed